Obesity Care Week 2021 Aims to Change the Way We Care About Obesity through Awareness and Action prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Your Say
Image credit
Author: Elizabeth Ciemins, Ph.D., M.P.H., M.A.
The prevalence of obesity among U.S. adults more than doubled from less than 15% in 1985 to 34% in 2005-2008. In 2017-2018, that prevalence skyrocketed to 42.4%! This staggering progression imitates the surge one might expect from a global pandemic. These rates, accompanied with the serious complications associated with obesity (e.g., diabetes, cardiovascular disease, chronic obstructive pulmonary disease) are a clear indicator that obesity is a disease that desperately needs to be identified and addressed. The COVID-19 pandemic has underscored the urgency of this need, as patients with chronic conditions like obesity and diabetes have been hospitalized, put on ventilators, and died at disproportionately high rates. In addition to the impact on patient health, obesity is expensive, with direct and indirect costs for treating it reaching nearly $2 trillion in 2016.
EDISON, NJ / ACCESSWIRE / February 10, 2021 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)("Hepion"), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH") and liver disease, today announced the appointment of Todd M.
(2)
EDISON, NJ / ACCESSWIRE / February 10, 2021 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)( Hepion ), a clinical stage biopharmaceutical company focused on Artificial Intelligence ( AI )-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ( NASH ) and liver disease, today announced the appointment of Todd M. Hobbs, M.D., to the newly created position of Chief Medical Officer ( CMO ), effective February 16, 2021.
In this role, Dr. Hobbs will help lead Hepion s engagement with the U.S. Food and Drug Administration ( FDA ), global and national thought leaders, key policymakers, and professional associations.
Dr. Hobbs joins Hepion from Novo Nordisk Inc., one of the world s leading healthcare companies. His 16 years of progressive experience at Novo Nordisk includes positions ranging from field medical affairs leadership at the start of his corporate career through to his most recent role as North American Chief Medical Officer and Vice President.
Four New Organizations Join National Coalition to Improve Diagnosis
Share Article
Four leading healthcare organizations, AMGA (American Medical Group Association), END SEPSIS, Health Care Improvement Foundation (HCIF), and Medical University of South Carolina (MUSC) have committed to take action to improve diagnostic quality and safety by joining the Coalition to Improve Diagnosis, which already includes more than 60 of the most prominent organizations in health care and patient advocacy.
“The Coalition will continue in its efforts to create awareness, advocate for increased research funding, and drive quality improvement in the field of diagnostic quality and safety, said Paul L. Epner, Chief Executive Officer and co-founder of the Society to Improve Diagnosis in Medicine (SIDM).